Leveraging Bi-Cygni Bispecific Antibody Drug Conjugates for High Selectivity Against Solid Tumors
Time: 8:30 am
day: Day One
Details:
- An introduction to BiVictriX’s proprietary bispecific ADC approach in a solid tumor setting
- Reviewing shared from the lead solid tumor bispecific ADC program
- Observing tumor growth inhibition and tumor regressions observed at well-tolerated doses in a murine model of ovarian cancer
